Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Academic Article uri icon

Overview

MeSH

  • Animals
  • Anthrax Vaccines
  • Mice
  • Survival Rate

MeSH Major

  • Adenoviridae
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Toxins
  • Gene Expression
  • Immunization, Passive

abstract

  • In the 2001 U.S. bioterror attacks, 33,000 individuals required postexposure prophylaxis, 18 subjects contracted anthrax (11 inhalation, 7 cutaneous), and despite optimal medical therapy, 5 deaths resulted. Rapid protection against anthrax is required in a bioterrorism scenario; this study describes an in vivo gene transfer-based therapy that uses a human adenovirus (Ad)-based vector (AdalphaPAscAb) encoding a single-chain antibody directed against protective antigen (PA), a critical component of Bacillus anthracis lethal toxin. Following AdalphaPAscAb administration to mice, anti-PA single-chain antibody and anti-PA neutralizing activity were detected in serum over a 2-week period. Substantial survival advantage from anthrax lethal toxin was conferred by AdalphaPAscAb following administration from 1 to 14 days prior to toxin challenge, compared to no survival associated with an Ad vector expressing a control single-chain antibody. Passive immunotherapy with an Ad-based vector may be a rapid, convenient approach for protecting a susceptible population against anthrax, including use as an adjunct to antibiotic therapy.

publication date

  • February 2005

has subject area

  • Adenoviridae
  • Animals
  • Anthrax Vaccines
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Toxins
  • Gene Expression
  • Immunization, Passive
  • Mice
  • Survival Rate

Research

keywords

  • Journal Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ymthe.2004.10.018

PubMed ID

  • 15668135

Additional Document Info

start page

  • 237

end page

  • 244

volume

  • 11

number

  • 2